Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial

BACKGROUND: BNT162b2 by Pfizer-BioNTech and mRNA-1273 by Moderna are the most commonly used vaccines to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Head-to-head comparison of the efficacy of these vaccines in immunocompromised patients is lacking. METHODS: Parall...

Descripción completa

Detalles Bibliográficos
Autores principales: Speich, Benjamin, Chammartin, Frédérique, Abela, Irene A, Amico, Patrizia, Stoeckle, Marcel P, Eichenberger, Anna L, Hasse, Barbara, Braun, Dominique L, Schuurmans, Macé M, Müller, Thomas F, Tamm, Michael, Audigé, Annette, Mueller, Nicolas J, Rauch, Andri, Günthard, Huldrych F, Koller, Michael T, Trkola, Alexandra, Briel, Matthias, Kusejko, Katharina, Bucher, Heiner C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903480/
https://www.ncbi.nlm.nih.gov/pubmed/35234868
http://dx.doi.org/10.1093/cid/ciac169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903480/
https://www.ncbi.nlm.nih.gov/pubmed/35234868
http://dx.doi.org/10.1093/cid/ciac169

Ejemplares similares